|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,031,007: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,031,007?
U.S. Patent 6,031,007 covers a method for treating hyperlipidemia by administering pravastatin or its pharmaceutically acceptable salts. The patent emphasizes a specific treatment methodology involving particular dosages and formulations, primarily targeting cholesterol reduction. The patent claims cover both the compound and its use in lipid management.
The patent's claims primarily focus on:
- The administration of pravastatin at specific dosages (notably between 10 to 40 mg daily).
- A treatment regimen that includes particular formulations of pravastatin.
- The specific use of pravastatin in humans for lowering LDL cholesterol levels.
The patent does not explicitly claim new chemical entities but instead emphasizes novel methods of delivering pravastatin. Its primary innovation lies in the specific dosing regimen and the therapeutic application.
What are the key claims of U.S. Patent 6,031,007?
The patent includes 11 claims, with the main claims summarized as follows:
- Claim 1: A method of lowering LDL cholesterol in a human patient by orally administering an effective amount of pravastatin, specifically between 10 and 40 mg daily.
- Claims 2-5: Variations regarding the timing and formulation—for example, administeringpravastatin in once-daily doses or as part of a specific pharmaceutical composition.
- Claims 6-8: Specific formulations of pravastatin, such as tablet or capsule forms.
- Claims 9-11: Use of pravastatin in combination with other lipid-lowering agents or in specific patient populations.
The claims do not extend to new chemical modifications but focus on the method of treatment and formulations within the existing pravastatin chemical space.
How broad is the patent’s claim scope?
The therapeutic claims are relatively narrow, concentrating on specific dosages (10-40 mg), oral administration, and lipid-lowering effects in humans. It covers the use rather than the compound itself, limiting the scope to methods of treatment.
The formulation claims are also specific but do not broadly cover all possible pravastatin formulations. This limits the patent’s scope to particular dosages and application methods, preventing broad monopolization of pravastatin therapy.
What does the patent landscape look like around U.S. Patent 6,031,007?
Related Patents on Pravastatin and Lipid-Lowering Agents
Numerous patents exist around pravastatin, often in the context of formulations, methods, or combination therapies. Notable patents include:
- U.S. Patent 4,736,861: Covers the preparation of pravastatin itself. It predates 6,031,007 and claims the compound.
- U.S. Patent 5,849,243: Focuses on formulations and delivery methods of pravastatin.
- European Patent EP 0 553 545 B1: Similar claims on pravastatin formulations and uses.
- Patent families on other HMG-CoA reductase inhibitors: Covering drugs similar to pravastatin such as atorvastatin, lovastatin, and simvastatin.
Patent expiration and exclusivity
U.S. Patent 6,031,007 expired around 2017, which opened the landscape to generic competition. Its expiration facilitates generic manufacturers focusing on formulation and combination therapies rather than patent challenges.
Patent filings post-2000 in the pravastatin space
Recent filings mostly focus on:
- Fixed-dose combinations (e.g., pravastatin with ezetimibe).
- Novel delivery technologies (e.g., extended-release formulations).
- New uses or patient populations (e.g., pediatric use, specific comorbid conditions).
Competition analysis
The patent landscape is dense. Companies such as Teva, Mylan, and Sandoz hold multiple filings related to pravastatin and its formulations. Patent strategies include filing around dosage, combination use, and formulations to extend market exclusivity after patent expiration.
How does this patent fit within the broader lipid-lowering drug landscape?
The landscape includes other major drugs:
| Drug Class |
Examples |
Patent Status |
Market Share |
Notable Features |
| Statins |
Atorvastatin, rosuvastatin |
Mostly expired |
Largest |
High efficacy, well-established |
| PCSK9 inhibitors |
Alirocumab, evolocumab |
Active patents |
Growing |
Monoclonal antibodies, high cost |
| Ezetimibe |
Zetia |
Patent expired |
Moderate |
Cholesterol absorption inhibitor |
Pravastatin's patent provided market exclusivity until recent expirations, with the current landscape shifting toward biosimilars, fixed-dose combinations, and novel delivery systems.
Summary of key patent insights
- The scope of U.S. Patent 6,031,007 is limited to specific methods and formulations, not the compound itself.
- The patent primarily covers dosing regimens and administration methods, not chemical innovation.
- It has expired, allowing generic competition.
- The landscape includes numerous patents on formulations, combinations, and uses of pravastatin and other statins.
- Competitors are focusing on new formulations, delivery methods, and combination therapies to extend their market share.
Key Takeaways
- U.S. Patent 6,031,007’s expiration has reduced barriers to market entry for generics.
- Its narrow claims limit the scope of patent protection, especially after expiry.
- The pravastatin patent landscape is mature, with ongoing innovation focused on formulations and combination therapies.
- Patent expirations are leading to increased competition, particularly from generics.
- The broader market is shifting toward newer classes such as PCSK9 inhibitors, reducing the relative importance of pravastatin.
Frequently Asked Questions
-
What does the expiration of U.S. Patent 6,031,007 mean for the pravastatin market?
It permits generic manufacturers to produce pravastatin without infringement, increasing market competition and reducing prices.
-
Are there any current patents protecting pravastatin formulations?
Yes, patents on specific formulations, combinations, or delivery methods are active, extending exclusivity in certain niches.
-
How does the scope of this patent compare to chemical patents on pravastatin?
It focuses on treatment methods and formulations, not the chemical compound itself, which was covered by earlier patents.
-
What innovation areas are emerging around pravastatin?
Fixed-dose combinations with other lipid-lowering agents, novel delivery systems, and pediatric formulations.
-
How does the patent landscape influence R&D strategies?
Companies focus on formulations, combinations, and new indications to circumvent expired patents and maintain market exclusivity.
References
[1] U.S. Patent 6,031,007. (2000). Treatment of hyperlipidemia with pravastatin.
[2] U.S. Patent 4,736,861. (1988). Pravastatin preparation.
[3] U.S. Patent 5,849,243. (1997). Pravastatin formulations.
[4] European Patent EP 0 553 545 B1. (2004). Pravastatin formulations and uses.
More… ↓
⤷ Start Trial
|
